Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

VERA

Vera Therapeutics Inc

Apr 15 • 04:00PM ET

46.53

Dollar change -1.44
Percentage change -3.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB SCHA DWAS IWN IWO LABU VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.28	Insider Own	26.90%	Shs Outstand	44.45M	Perf Week	20.45%
Market Cap	2.50B	Forward P/E	-	EPS next Y	-2.34	Insider Trans	-11.34%	Shs Float	39.26M	Perf Month	6.97%
Income	-95.99M	PEG	-	EPS next Q	-0.55	Inst Own	61.47%	Short Float	16.12%	Perf Quarter	145.54%
Sales	0.00M	P/S	-	EPS this Y	-0.16%	Inst Trans	1.76%	Short Ratio	4.53	Perf Half Y	347.40%
Book/sh	2.29	P/B	20.34	EPS next Y	-3.97%	ROA	-62.54%	Short Interest	6.33M	Perf Year	622.52%
Cash/sh	2.99	P/C	15.55	EPS next 5Y	-	ROE	-107.50%	52W Range	6.05 - 50.78	Perf YTD	202.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.22%	ROI	-62.76%	52W High	-8.37%	Beta	1.03
Dividend TTM	-	Quick Ratio	7.42	Sales past 5Y	0.00%	Gross Margin	-	52W Low	669.09%	ATR (14)	3.45
Dividend Ex-Date	-	Current Ratio	7.42	EPS Y/Y TTM	31.36%	Oper. Margin	0.00%	RSI (14)	58.94	Volatility	11.31% 8.17%
Employees	51	Debt/Eq	0.53	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.36	Target Price	55.80
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	50.54%	Payout	-	Rel Volume	0.80	Prev Close	47.97
Sales Surprise	-	EPS Surprise	-8.12%	Sales Q/Q	-	Earnings	Mar 20 BMO	Avg Volume	1.40M	Price	46.53
SMA20	10.82%	SMA50	7.83%	SMA200	105.96%	Trades		Volume	1,124,222	Change	-3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
12:52PM	Loading…
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)
08:00AM	Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-01-24 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Jan-29-24 11:50PM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) +11.46%
06:15AM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-25-24 06:30AM	Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy (GlobeNewswire) +48.71%
Jan-12-24 06:44PM	Why Vera Therapeutics Stock Soared by 22% This Week (Motley Fool)
08:01AM	Loading…
Jan-08-24 08:01AM	Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer (GlobeNewswire) +16.74%
08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 (GlobeNewswire)
Dec-27-23 08:00AM	Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-23 10:15AM	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street (Motley Fool) +8.70%
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Vera Therapeutics Inc (GuruFocus.com) +6.74%
09:55AM	Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade (Zacks)
Nov-09-23 09:29AM	Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business Updates (GuruFocus.com)
08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-23 10:00AM	Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-30-23 08:00AM	Vera Therapeutics Scheduled to Present at November Investor Conferences (GlobeNewswire) +8.32%
Oct-18-23 09:35AM	Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks) -5.09%
Oct-17-23 09:35AM	Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks)
Oct-16-23 09:35AM	Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround (Zacks)
Oct-13-23 10:22AM	Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Sep-26-23 04:02PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +11.32%
08:00AM	Loading…
Aug-31-23 08:00AM	Vera Therapeutics Scheduled to Present at September Investor Conferences (GlobeNewswire) -5.70%
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 04:03PM	What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock (Zacks)
Aug-10-23 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire) +6.22%
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-24-23 09:01AM	Positive Signs As Multiple Insiders Buy Vera Therapeutics Stock (Simply Wall St.) -6.82%
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com) +5.20%
Jun-27-23 08:05AM	Vera Therapeutics Likely Needs Time to Digest Its Recent Dramatic Gains (TheStreet.com)
Jun-20-23 07:04PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +16.94%
09:33AM	2 Surging Healthcare Stocks With More Fuel in the Tank (Motley Fool)
Jun-17-23 10:10AM	Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress (GlobeNewswire)
Jun-15-23 04:44PM	Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN (GlobeNewswire)
Jun-12-23 12:05PM	Why Shares of Vera Therapeutics Are Soaring Monday (Motley Fool) +15.83%
Jun-11-23 01:08PM	7 Stocks That Wall Street Analysts Are Loving in June (InvestorPlace)
Jun-08-23 08:00AM	Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-07-23 08:00AM	Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire)
May-11-23 08:36AM	Should You Buy Vera Therapeutics (VERA) Ahead of Earnings? (Zacks)
07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire)
May-04-23 08:00AM	Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
Mar-28-23 07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 04:05PM	Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-14-23 07:48AM	Chief Financial Officer Sean Grant Just Bought 207% More Shares In Vera Therapeutics, Inc. (NASDAQ:VERA) (Simply Wall St.)
Feb-09-23 06:51AM	Daily Vickers Top Buyers & Sellers for 02/09/2023 (Argus Research)
05:54AM	With 35% stake, Vera Therapeutics, Inc. (NASDAQ:VERA) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-06-23 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Feb-01-23 09:52PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
04:01PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire)
Jan-30-23 07:35AM	Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs (Benzinga) -6.06%
06:00AM	Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria (GlobeNewswire)
Jan-25-23 08:00AM	Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN) (GlobeNewswire)
Jan-22-23 07:39AM	Why Vera Therapeutics Stock Bolted Higher This Week (Motley Fool)
Jan-06-23 05:02AM	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax (Zacks)
Jan-04-23 04:07PM	Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update And Chinook Popped (Investor's Business Daily) -64.70%
12:20PM	VERA Dips Despite Positive Data From IgA Nephropathy Study (Zacks)
10:22AM	These 2 Nasdaq Biotechs Are Making Big Moves Wednesday (Motley Fool)
06:52AM	Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study (Benzinga)
Jan-03-23 04:01PM	Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire) -5.43%
Dec-20-22 04:05PM	Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-22 07:38AM	One Vera Therapeutics, Inc. (NASDAQ:VERA) insider upped their stake by 329% in the previous year (Simply Wall St.)
Nov-22-22 07:30AM	Vera Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-17-22 07:30AM	Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP (GlobeNewswire)
Nov-09-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.00%
Nov-05-22 04:50PM	Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 07:30AM	Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Sep-15-22 09:55AM	Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a Bet (Zacks)
Sep-07-22 07:30AM	Vera Therapeutics to Present at Upcoming Conferences in September 2022 (GlobeNewswire) +5.93%
Aug-29-22 09:55AM	Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High? (Zacks) +11.10%
Aug-12-22 09:55AM	Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect? (Zacks) +5.17%
Aug-10-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +9.03%
Aug-04-22 07:30AM	Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-06-22 07:30AM	Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire)
Jun-18-22 08:20AM	Insider Buying: The Vera Therapeutics, Inc. (NASDAQ:VERA) Chief Financial Officer Just Bought 329% More Shares (Simply Wall St.)
Jun-04-22 02:30PM	Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients (GlobeNewswire)
Jun-02-22 07:30AM	Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-20-22 04:05PM	Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress (GlobeNewswire)
May-16-22 07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 04:05PM	Vera Therapeutics to Present at Upcoming Conferences in May 2022 (GlobeNewswire)
May-03-22 04:33PM	Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus (GlobeNewswire) -5.66%
May-02-22 07:06PM	Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022 (GlobeNewswire)
Apr-12-22 07:30AM	Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors (GlobeNewswire)
Mar-24-22 06:30AM	Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-21-22 07:30AM	Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher (GlobeNewswire) -7.30%
Mar-17-22 07:30AM	Vera Therapeutics to Host Business Update Call (GlobeNewswire)
Mar-01-22 07:30AM	Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-22-22 05:29AM	We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-14-22 04:01PM	Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-22 08:46AM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) -6.56%
Feb-07-22 05:24PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire) +7.72%
Jan-18-22 07:30AM	Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis (GlobeNewswire)
Jan-04-22 07:30AM	Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Apr 10 '24	Sale	40.00	5,714	228,560	53,171	Apr 12 04:02 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Option Exercise	14.87	99,828	1,484,442	166,165	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.61	99,828	3,954,516	66,337	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.42	18,649	735,205	0	Apr 05 09:32 PM
Katabi Maha	Director	Mar 25 '24	Sale	40.50	340,000	13,770,000	2,793,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 22 '24	Sale	40.51	413,450	16,748,860	3,133,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 21 '24	Sale	44.20	81,009	3,580,723	3,547,437	Mar 25 09:46 PM
Katabi Maha	Director	Jan 30 '24	Buy	31.00	161,290	4,999,990	3,628,446	Feb 01 05:58 PM
COMMODORE CAPITAL LP	10% Owner	Jan 10 '24	Sale	18.00	1,050,000	18,900,000	4,400,000	Jan 12 09:55 PM
Fordyce Marshall	President and CEO	Dec 29 '23	Option Exercise	2.87	13,516	38,854	256,877	Jan 03 04:15 PM
Fordyce Marshall	President and CEO	Aug 21 '23	Sale	16.66	5,210	86,779	243,361	Aug 23 05:56 PM
Curley Joanne	Chief Development Officer	Aug 21 '23	Sale	16.66	1,490	24,817	26,962	Aug 23 05:57 PM
Lin Celia	Chief Medical Officer	Aug 21 '23	Sale	16.65	1,490	24,816	11,010	Aug 23 05:59 PM
Young Joseph R	SVP, Finance, Chief Acct Offcr	Jul 05 '23	Option Exercise	3.94	10,000	39,396	32,679	Jul 06 04:05 PM
Grant Sean	Chief Financial Officer	Jun 23 '23	Buy	16.60	5,000	83,000	5,992	Jun 23 04:05 PM
COMMODORE CAPITAL LP	10% Owner	Jun 20 '23	Buy	15.17	448,217	6,799,004	5,450,000	Jun 22 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERA

Vera Therapeutics Inc

Upgrade your FINVIZ experience